Tibet Pharmaceutical (600211.SH) released its semi-annual performance report, with a net profit attributable to the parent company of 567 million yuan, a year-on-year decrease of 8.96%.

China Fortune Financial News APP reported that Tibet Pharmaceuticals (600211.SH) disclosed its semi-annual report for 2025. During the reporting period, the company achieved a revenue of 1.651 billion yuan, an increase of 2.23% year-on-year; the net profit attributable to shareholders of the listed company was 567 million yuan, a decrease of 8.96% year-on-year; the non-recurring net profit was 543 million yuan, an increase of 3.69% year-on-year; the basic earnings per share was 1.76 yuan. The company plans to distribute a cash dividend of 8.81 yuan (tax inclusive) per 10 shares to all shareholders.